All News
RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia
d
MedPage Today
Fibromyalgia patients hoping to see a more effective and convenient formulation of cyclobenzaprine at their local pharmacies must wait for an ongoing phase III trial -- the product's third -- to finish, as the first two delivered mixed results.
Read Article
Juvenile and Adult-onset Scleroderma Differ
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
Read Article
ICYMI: Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read Article
FDA approves a NGF inhbitor bedinvetmab (Librela) to treat osteoarthritis in Dogs!. Recently FDA approved NGF inhibitor cats w/ OA --- Yet 4 different NGF inhibitors failed in their development for human OA - are cats & dogs treated better than us? https://t.co/Tbca0PiEL2 https://t.co/Y7mViSa5J4
Links:
Dr. John Cush RheumNow ( View Tweet)
One in Ten is Bad!
This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!
https://t.co/5SXPotfhs0 https://t.co/jXwsWoltsy
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Giving Good Care in Diversity takes Time
Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes.
https://t.co/NRHBwHLqSi https://t.co/nj8eaGiU50
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Meetings should be like Oktoberfest
https://t.co/pZGOYXINir https://t.co/RIXmpRztaL
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Modern Management of PsA Faculty Panel Q&A ,
https://t.co/WIESJSL8WF https://t.co/0k7FyYkFtc
Links:
Dr. John Cush RheumNow ( View Tweet)
Chinese study of 4091 SLE pts, 3% (106) dx w/ osteonecrosis (AVN). AVN risk factors included:
- SLE onset age ≤ 30 (HR 1.6)
- Arthritis (HR 1.6)
- Organ damage (HR 2.6)
- RNP+ (HR 1.7)
- High steroid doses (HR 1.7) https://t.co/DnqhEIWztY https://t.co/aP0uh0oh1x
Links:
Dr. John Cush RheumNow ( View Tweet)
Proposed AOSD criteria: 80 AOSD vs 60 autoimmune pts: \Nneed 7 points = AOSD dx (sensitivity 92%, specificity 93%, AUC 93%):
- typical rash 3 pts
- fever ≥ 39°C 3 pts
- pharyngitis 2 pts
- arthritis 2 pts
- glycosylated ferritin≤ 20% 1 pt https://t.co/iLUryBVa7C https://t.co/HTWgAucBIm
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with AIIRD, that may be immunocompromised.
https://t.co/eAN3X3kAHV https://t.co/qpFc7hlG7u
Links:
Dr. John Cush RheumNow ( View Tweet)
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis
A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).
https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB
Links:
Dr. John Cush RheumNow ( View Tweet)
Heart to Heart: Cardiovascular Risk in RA
Tune in as Dr. Christina Charles-Schoeman and Dr. Roy Fleischmann discuss how to help mitigate CVD risk in patients with RA in the latest therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/52g6cnI5Wi https://t.co/E87OUHWFib
Links:
Dr. John Cush RheumNow ( View Tweet)
Comprehensive full read review of Cutaneous Lupus Erythematosus - pathogenesis, pathology and treatment options. https://t.co/J7C0511kBJ https://t.co/ILhcpeT5cx
Links:
Dr. John Cush RheumNow ( View Tweet)
Pregnancy in PsA
RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine
https://t.co/QR0Mb7F1x3 https://t.co/rj6HtoUTpE
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in Psoriasis and PsA
RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine
https://t.co/eVwQ6ITzD7 https://t.co/GZxVx77aV1
Links:
Dr. John Cush RheumNow ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/DMsjFzmjPn https://t.co/X1fg9ylo7g
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 481 incident RA:
- no risk of RA w/ tea, alcohol & sugar-soft drinks
- Incr RA risk seen w/ coffee [≥4 vs ≤1cup, HR=1.24;p=0.04] & diet drinks [HR=1.66;never-smokers]
- Reduced RA risk w/ mod EtOH (ever-smokers;HR=0.63) & wine (seropos RA) https://t.co/RQFpxXUT11 https://t.co/ew2imYMLnJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances
This webinar will feature highlights from these lectures followed by live audience Q & A:
-New Therapies for PMR & GCA
-Assessment of GCA and PMR
-GPA Treatment Choices
https://t.co/PRj6QQnxIS https://t.co/Y4aCyTrg0Z
Links:
Dr. John Cush RheumNow ( View Tweet)
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
https://t.co/a2VbAO0Fc6 https://t.co/69Yl9OTtKY
Links:
Dr. John Cush RheumNow ( View Tweet)
